Experimental data show that SIN can prevent IL-1β-induced inflammation of human fibroblast-like synovial cells (RAFLS) by inhibiting TLR4/MyD88/NF-κB signal pathway,[21] which indicates that SIN may be a potential drug for the treatment of RA bone injury. This evidence concerns the gene IL1B and rheumatoid arthritis.